Orchid Cellmark (NASDAQ: ORCH) CEO Interview

This interview has expired.
Click here to find stocks, with exciting stories, and management committed to maximizing shareholder value.

Special deals for our readers
Are you qualified for the Visa Black Card?
The World’s Most Prestigious and Versatile Credit Card. Apply Now!

Be a more profitable investor:
What’s Jim Cramer trading in his personal portfolio? Click here

Get an Equifax 3-in-1 Credit Report Now!

Why are you still paying too much with Schwab, and and E-trade?? Step up to the #1 discount broker: TradeKing.
Find out why TradeKing.com was ranked #1 Discount Broker by SmartMoney Magazine two years running! (August 2006 & 2007).

Invest Smarter! Get 4 Bonus Weeks of Investor’s Business Daily Digital Edition!

LifeLock is the only Identity Theft Prevention Solution backed by a one-million dollar guarantee!Click here to get a 10% discount.

Get FICO Score Watch Now!

Free Quicken Online automatically categorizes your expenses.

Click here to get access to powerful investing tools only available at Investor’s Business Daily.

Get a free look at Jim Cramer’s Action Alerts PLUS portfolio. Click here

Orchid Cellmark
Thomas Bologna, CEO

Orchid Cellmark Inc. is engaged in the provision of deoxyribonucleic acid (DNA) testing services that generate genetic profile information by analyzing an organism’s genetic identity. The Company’s business focuses on DNA testing for human identity and agricultural applications. In the human identity area, the Company provides DNA testing services for forensic, family relationship, and security applications. In agricultural applications, the Company provides DNA testing services for selective trait breeding. The Company has operations in the United States and in the United Kingdom. The Company’s forensic, family relationship, and security DNA testing services are conducted in both the United States and the United Kingdom, while all of its agricultural DNA testing services are conducted in the United Kingdom.

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.